Government-Owned Inventions; Availability for Licensing, 10022-10023 [2017-02674]

Download as PDF 10022 Federal Register / Vol. 82, No. 26 / Thursday, February 9, 2017 / Notices sradovich on DSK3GMQ082PROD with NOTICES could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications/ contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Cancer Institute Special Emphasis Panel; Questions in Cancer System Biology. Date: March 2, 2017. Time: 8:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 2E908, Rockville, MD 20850. Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Resources and Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W234, Bethesda, MD 20892–9750, 240–276–6368, stoicaa2@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Tools for Monitoring RNA. Date: March 14, 2017. Time: 11:00 a.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 4W030, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Jeffrey E. DeClue, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W238, Bethesda, MD 20892– 9750, 240–276–6371, decluej@nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Co-Clinical Imaging. Date: March 30, 2017. Time: 11:00 a.m. to 6:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W030, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Kenneth L. Bielat, Ph.D., Scientific Review Officer, Research Technology and Contract Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W244, Rockville, MD 20892– 9750, 240–276–6373, bielatk@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Collaborative Consortia for the Study of HIVAssociated Cancers (U54) RFA–CA–16–018. Date: April 5–6, 2017. Time: 8:00 a.m. to 5:00 p.m. Agenda: To review and evaluate grant applications. Place: Bethesda North Marriott Hotel & Conference Center, 5701 Marinelli Road, North Bethesda, MD 20852. Contact Person: Adriana Stoica, Ph.D., Scientific Review Officer, Resources and VerDate Sep<11>2014 18:11 Feb 08, 2017 Jkt 241001 Training Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W234, Rockville, MD 20892–9750, 240–276–6368, stoicaa2@mail.nih.gov. Name of Committee: National Cancer Institute Special Emphasis Panel; Cancer Center Support Grant. Date: April 7, 2017. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate grant applications. Place: National Cancer Institute Shady Grove, 9609 Medical Center Drive, Room 7W030, Rockville, MD 20850 (Telephone Conference Call). Contact Person: Caterina Bianco, MD, Ph.D., Scientific Review Officer, Research Programs Review Branch, Division of Extramural Activities, National Cancer Institute, NIH, 9609 Medical Center Drive, Room 7W110, Bethesda, MD 20892–9750, 240–276–6459, biancoc@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Dated: February 3, 2017. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–02621 Filed 2–8–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Government-Owned Inventions; Availability for Licensing AGENCY: National Institutes of Health, HHS. ACTION: Notice. The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing. FOR FURTHER INFORMATION CONTACT: Licensing information and copies of the patent applications listed below may be obtained by communicating with the indicated licensing contact at the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 SUMMARY: PO 00000 Frm 00040 Fmt 4703 Sfmt 4703 Fishers Lane, Rockville, MD, 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished patent applications. SUPPLEMENTARY INFORMATION: Technology description follows. Small Molecule Imaging of Fungi by Positron Emission Tomography Scanning Description of Technology This technology relates to the field of radioactive, isotopically-labeled calcofluor derivatives and uses of such compounds to detect a broad spectrum of filamentous fungi including pathogenic species such as Aspergillus and Mucorales, by diagnostic imaging methods such as positron emission tomography (PET) scanning. Aspergillosis and other filamentous fungal infections are increasingly common fungal lung infection with high mortality rates (over 50%) in immune compromised patients, such as those receiving chemotherapy, stem cell/organ transplantation, or HIV patients. Oneyear survival of the infected patients ranges from 59% (organ transplant recipients) to as low as 25% (stem cell transplant recipients). Delayed diagnosis and therapy are likely to lead to poor outcomes and death. This disease is often first detected as nodules on CT scans. A diagnosis is typically made following invasive lung bronchoscopy or biopsy. However, as these patients are immunocompromised, these invasive procedures may themselves lead to significant complications and infections. Therefore, to enable timely treatment and minimize complications, there is a critical need for non-invasive means to detect and diagnose fungal infections. The calcofluor derivatives disclosed in the patent application may be utilized as imaging agents specific for fungal infections and could potentially become a standard, non-invasive procedure in the work-up of immunocompromised patients with lung infections. This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration. Potential Commercial Applications • Diagnostics of Aspergillosis and other filamentous fungal infections. Competitive Advantages • Non-invasive. E:\FR\FM\09FEN1.SGM 09FEN1 Federal Register / Vol. 82, No. 26 / Thursday, February 9, 2017 / Notices • Low toxicity. • Specific for Aspergillus. 10023 DEPARTMENT OF HEALTH AND HUMAN SERVICES 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS) Development Stage National Institutes of Health • In vivo data available (animal). Inventors: Peter R. Williamson (NIAID), Dale O. Kiesewetter (NIBIB), John C. Panepinto (University of Buffalo), and Jin Qiu (NIAID). National Cancer Institute; Notice of Closed Meetings Dated: February 3, 2017. Melanie J. Pantoja, Program Analyst, Office of Federal Advisory Committee Policy. Publications sradovich on DSK3GMQ082PROD with NOTICES 1. Palmer GE, et al., The diverse roles of autophagy in medically important fungi, Autophagy. 2008 Nov; 4(8):982–8. [PMID 18927489] 2. Panepinto JC, et al., Deletion of the Aspergillus fumigatus gene encoding the Ras-related protein RhbA reduces virulence in a model of invasive pulmonary aspergillosis, Infect Immun. 2003 May; 71(5):2819–26. [PMID 12704156] 3. Desoubeaux D, et al., Diagnosis of invasive pulmonary aspergillosis: Updates and recommendations, Med Mal Infect. 2014 Mar; 44(3):89–101. [PMID 24548415] Intellectual Property: HHS Reference Nos. E–449–2013/0,1—U.S. Provisional Application No. 61/894,754, filed October 23, 2013; PCT Application No. PCT/US2014/061917, filed October 23, 2014 (published as WO 2015/061540 on April 30, 2015); European Application No. 14800182.9, filed October 23, 2014 (pending); Australian Application No. 2014340035, filed October 23, 2014 (pending); Canadian Application No. 2927952, filed October 23, 2014; and U.S. Application No. 15/030,554, filed April 19, 2016 (pending). Licensing Contact: Dr. David Yang, 240–627–3413; polung.yang@nih.gov. Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize for development of this invention. For collaboration opportunities, please contact Dr. David Yang, 240–627–3413; polung.yang@ nih.gov. Dated: February 6, 2017. Suzanne Frisbie, Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases. [FR Doc. 2017–02674 Filed 2–8–17; 8:45 am] BILLING CODE 4140–01–P VerDate Sep<11>2014 18:11 Feb 08, 2017 Jkt 241001 Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of meetings of the Board of Scientific Counselors for Basic Sciences, National Cancer Institute and the Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute. The meetings will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Cancer Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors for Clinical Sciences and Epidemiology, National Cancer Institute. Date: March 6, 2017. Time: 8:30 p.m. to 4:00 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institutes of Health, 31 Center Drive, Building 31, C–Wing, 6th Floor, Conference Room 6, Bethesda, MD 20892. Contact Person: Brian E. Wojcik, Ph.D., Senior Review Administrator, Institute Review Office, Office of the Director, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 3W414, Bethesda, MD 20892, 240–276–5664, wojcikb@mail.nih.gov. Name of Committee: Board of Scientific Counselors for Basic Sciences, National Cancer Institute. Date: March 7, 2017. Time: 9:00 a.m. to 12:15 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. Place: National Institutes of Health, 31 Center Drive, Building 31, C–Wing, 6th Floor, Conference Room 6, Bethesda, MD 20892. Contact Person: Mehrdad Tondravi, Ph.D., Chief, Institute Review Office, Office of the Director, National Cancer Institute, National Institutes of Health, 9609 Medical Center Drive, Room 3W–302, Bethesda, MD 20892, 240–276–5664, tondravim@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; PO 00000 Frm 00041 Fmt 4703 Sfmt 9990 [FR Doc. 2017–02615 Filed 2–8–17; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The contract proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the contract proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID Peer Review Meeting. Date: March 6, 2017. Time: 1:00 p.m. to 3:00 p.m. Agenda: To review and evaluate contract proposals. Place: National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20892 (Telephone Conference Call). Contact Person: Kelly Y. Poe, Ph.D., Scientific Review Office, Scientific Review Program, Division of Extramural Activities, Room 3F40B, National Institutes of Health, NIAID, 5601 Fishers Lane, MSC 9823, Bethesda, MD 20892–9823, (240) 669–5036, poeky@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS) Dated: February 3, 2017. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2017–02620 Filed 2–8–17; 8:45 am] BILLING CODE 4140–01–P E:\FR\FM\09FEN1.SGM 09FEN1

Agencies

[Federal Register Volume 82, Number 26 (Thursday, February 9, 2017)]
[Notices]
[Pages 10022-10023]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-02674]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The invention listed below is owned by an agency of the U.S. 
Government and is available for licensing to achieve expeditious 
commercialization of results of federally-funded research and 
development. Foreign patent applications are filed on selected 
inventions to extend market coverage for companies and may also be 
available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information and copies of 
the patent applications listed below may be obtained by communicating 
with the indicated licensing contact at the Technology Transfer and 
Intellectual Property Office, National Institute of Allergy and 
Infectious Diseases, 5601 Fishers Lane, Rockville, MD, 20852; tel. 301-
496-2644. A signed Confidential Disclosure Agreement will be required 
to receive copies of unpublished patent applications.

SUPPLEMENTARY INFORMATION: Technology description follows.

Small Molecule Imaging of Fungi by Positron Emission Tomography 
Scanning

Description of Technology

    This technology relates to the field of radioactive, isotopically-
labeled calcofluor derivatives and uses of such compounds to detect a 
broad spectrum of filamentous fungi including pathogenic species such 
as Aspergillus and Mucorales, by diagnostic imaging methods such as 
positron emission tomography (PET) scanning.
    Aspergillosis and other filamentous fungal infections are 
increasingly common fungal lung infection with high mortality rates 
(over 50%) in immune compromised patients, such as those receiving 
chemotherapy, stem cell/organ transplantation, or HIV patients. One-
year survival of the infected patients ranges from 59% (organ 
transplant recipients) to as low as 25% (stem cell transplant 
recipients). Delayed diagnosis and therapy are likely to lead to poor 
outcomes and death. This disease is often first detected as nodules on 
CT scans. A diagnosis is typically made following invasive lung 
bronchoscopy or biopsy. However, as these patients are 
immunocompromised, these invasive procedures may themselves lead to 
significant complications and infections. Therefore, to enable timely 
treatment and minimize complications, there is a critical need for non-
invasive means to detect and diagnose fungal infections.
    The calcofluor derivatives disclosed in the patent application may 
be utilized as imaging agents specific for fungal infections and could 
potentially become a standard, non-invasive procedure in the work-up of 
immunocompromised patients with lung infections.
    This technology is available for licensing for commercial 
development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as 
well as for further development and evaluation under a research 
collaboration.

Potential Commercial Applications

     Diagnostics of Aspergillosis and other filamentous fungal 
infections.

Competitive Advantages

     Non-invasive.

[[Page 10023]]

     Low toxicity.
     Specific for Aspergillus.

Development Stage

     In vivo data available (animal).
    Inventors: Peter R. Williamson (NIAID), Dale O. Kiesewetter 
(NIBIB), John C. Panepinto (University of Buffalo), and Jin Qiu 
(NIAID).

Publications

    1. Palmer GE, et al., The diverse roles of autophagy in medically 
important fungi, Autophagy. 2008 Nov; 4(8):982-8. [PMID 18927489]
    2. Panepinto JC, et al., Deletion of the Aspergillus fumigatus gene 
encoding the Ras-related protein RhbA reduces virulence in a model of 
invasive pulmonary aspergillosis, Infect Immun. 2003 May; 71(5):2819-
26. [PMID 12704156]
    3. Desoubeaux D, et al., Diagnosis of invasive pulmonary 
aspergillosis: Updates and recommendations, Med Mal Infect. 2014 Mar; 
44(3):89-101. [PMID 24548415]
    Intellectual Property: HHS Reference Nos. E-449-2013/0,1--U.S. 
Provisional Application No. 61/894,754, filed October 23, 2013; PCT 
Application No. PCT/US2014/061917, filed October 23, 2014 (published as 
WO 2015/061540 on April 30, 2015); European Application No. 14800182.9, 
filed October 23, 2014 (pending); Australian Application No. 
2014340035, filed October 23, 2014 (pending); Canadian Application No. 
2927952, filed October 23, 2014; and U.S. Application No. 15/030,554, 
filed April 19, 2016 (pending).
    Licensing Contact: Dr. David Yang, 240-627-3413; 
polung.yang@nih.gov.
    Collaborative Research Opportunity: The National Institute of 
Allergy and Infectious Diseases is seeking statements of capability or 
interest from parties interested in collaborative research to further 
develop, evaluate or commercialize for development of this invention. 
For collaboration opportunities, please contact Dr. David Yang, 240-
627-3413; polung.yang@nih.gov.

    Dated: February 6, 2017.
Suzanne Frisbie,
Deputy Director, Technology Transfer and Intellectual Property Office, 
National Institute of Allergy and Infectious Diseases.
[FR Doc. 2017-02674 Filed 2-8-17; 8:45 am]
BILLING CODE 4140-01-P